Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Settles On Classifications For Nearly 600 Devices, IVDs

Executive Summary

The final list of medical devices and IVDs classifies products according to India’s imminent new rules for medtech products. It contains about 100 fewer entries than the original draft issued in June.

You may also be interested in...



Pandemic Perspectives: Riding The Waves Of Asia’s Healthtech Innovation Explosion

One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.

Regulator Answers Industry's Questions About India’s New Medical Device Rules

A new FAQ document from India's health-care products regulator clarifies requirements relating to manufacturing licenses and other issues under the new medical device rules that came into effect on Jan. 1.

Indian Medtech Finds Errors In New Draft List Classifying Devices, IVDs

India’s industry association claims that some of the products on the regulator’s new draft list classifying over 700 medical devices and IVDs have been categorized incorrectly. The list is expected to be finalized at least three months before new medical device rules come into effect in January 2018.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel